Publication:
Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT.

dc.contributor.authorHerrera-Hidalgo, Laura
dc.contributor.authorLomas-Cabezas, Jose Manuel
dc.contributor.authorLopez-Cortes, Luis Eduardo
dc.contributor.authorLuque-Marquez, Rafael
dc.contributor.authorLopez-Cortes, Luis Fernando
dc.contributor.authorMartinez-Marcos, Francisco J
dc.contributor.authorde-la-Torre-Lima, Javier
dc.contributor.authorPlata-Ciezar, Antonio
dc.contributor.authorHidalgo-Tenorio, Carmen
dc.contributor.authorGarcia-Lopez, Maria Victoria
dc.contributor.authorVinuesa, David
dc.contributor.authorGutierrez-Valencia, Alicia
dc.contributor.authorGil-Navarro, Maria Victoria
dc.contributor.authorDe-Alarcon, Aristides
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean Regional Development Fund (“A way to achieve Europe”)
dc.date.accessioned2023-05-03T14:04:12Z
dc.date.available2023-05-03T14:04:12Z
dc.date.issued2021-12-21
dc.description.abstractAmpicillin plus ceftriaxone (AC) is a well-recognized inpatient regimen for Enterococcus faecalis infective endocarditis (IE). In this regimen, ceftriaxone is usually administered 2 g every 2 h (AC12). The administration of AC in outpatient parenteral antibiotic treatment (OPAT) programs is challenging because multiple daily doses are required. AC regimens useful for OPAT programs include once-daily high-dose administration of ceftriaxone (AC24) or AC co-diluted and jointly administered in bolus every 4 h (ACjoined). In this retrospective analysis of prospectively collected cases, we aimed to assess the clinical effectivity and safety of three AC regimens for the treatment of E. faecalis IE. Fifty-nine patients were treated with AC combinations (AC12 n = 32, AC24 n = 17, and ACjoined n = 10). Six relapses occurred in the whole cohort: five (29.4%) treated with AC24 regimen and one (10.0%) with ACjoined. Patients were cured in 30 (93.3%), 16 (94.1%), and eight (80.0%) cases in the AC12, AC24 and ACjoined groups, respectively. Unplanned readmission occurred in eight (25.0%), six (35.3%), and two (20.0%) patients in the AC12, AC24 and ACjoined groups, respectively. The outcome of patients with E. faecalis IE treated with AC in OPAT programs relies on an optimization of the delivery of the combination. AC24 exhibit an unexpected rate of failures, however, ACjoined might be an effective alternative which clinical results should corroborate in further studies.
dc.description.sponsorshipThe authors received no financial support for the research, authorship, and/or publication of this article. GVA was supported by the Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (“A way to achieve Europe”), Subprograma Miguel Servet (grant CP19/00159). HHL was supported by the Instituto de Salud Carlos III, Subprograma Rio Hortega (grant CM19/00152).
dc.description.versionSi
dc.identifier.citationHerrera-Hidalgo L, Lomas-Cabezas JM, López-Cortés LE, Luque-Márquez R, López-Cortés LF, Martínez-Marcos FJ, et al. Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. J Clin Med. 2021 Dec 21;11(1):7
dc.identifier.doi10.3390/jcm11010007
dc.identifier.issn2077-0383
dc.identifier.pmcPMC8745305
dc.identifier.pmid35011748
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745305/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2077-0383/11/1/7/pdf?version=1640081737
dc.identifier.urihttp://hdl.handle.net/10668/21221
dc.issue.number1
dc.journal.titleJournal of clinical medicine
dc.journal.titleabbreviationJ Clin Med
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario Juan Ramón Jiménez
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Costa del Sol
dc.organizationHospital Universitario Regional de Málaga
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.page.number8
dc.provenanceRealizada la curación de contenido 10/03/2025
dc.publisherMDPI
dc.pubmedtypeJournal Article
dc.relation.projectIDCP19/00159
dc.relation.projectIDCM19/00152
dc.relation.publisherversionhttps://www.mdpi.com/resolver?pii=jcm11010007
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectEnterococcus faecalis
dc.subjectAmpicillin
dc.subjectCeftriaxone
dc.subjectInfective endocarditis
dc.subjectOutpatient parenteral antibiotic treatment
dc.subject.decsCeftriaxona
dc.subject.decsOrganización y administración
dc.subject.decsRecurrencia
dc.subject.decsPacientes internos
dc.subject.decsPacientes ambulatorios
dc.subject.decsAmpicilina
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshCeftriaxone
dc.subject.meshInpatients
dc.subject.meshRetrospective Studies
dc.subject.meshPatient Readmission
dc.subject.meshAmpicillin
dc.titleAmpicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8745305.pdf
Size:
260.92 KB
Format:
Adobe Portable Document Format